BeOne Medicines Ltd. (ONC) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 37 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Wed, Aug 5, 2026before open 36 8-K
Q1 FY2026Wed, May 6, 2026before open 36 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Wed, May 7, 2025before open 37 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026." exhibit
Read from the sentence: revenue $6.9 billion to $7 billion, FY2026
Q3 FY2026 "Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI." exhibit
Q3 FY2026 "Full Year 2026 Guidance BeOne’s financial guidance is summarized below: Prior FY 2026 Guidance Current FY 2026 Guidance 1 Total revenue $6.6B - $6.8B $6.9B - $7.0B GAAP gross margin % High-80% range High-80% range GAAP operating expenses 2 (combined R&D and SG&A) $4.8B - $5.0B $4.9B - $5.0B GAAP operating income 2 $1.0B - $1.1B $1.2B - $1.3B Non-GAAP operating income 2,3 $1.7B - $1.8B $1.9B - $2.0B 1 Assumes November 1, 2026 foreign exchange rates. 2 Does not assume any potential new, material business development activity or unusual/non-recurring items. 3 Non-GAAP operating income is a financ" exhibit
Q3 FY2026 "BeOne’s total revenue guidance for full year 2026 of $6.9 billion to $7.0 billion reflects performance through the third quarter and the Company’s expectations for the remainder of the year." exhibit
Q3 FY2026 "Income tax outlook : Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized." exhibit
Q2 FY2026 "Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion SAN CARLOS, Calif. – August 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026." exhibit
Read from the sentence: revenue $6.6 billion to $6.8 billion, FY2026
Q2 FY2026 "Updated Full Year 2026 Guidance BeOne’s financial guidance is summarized below: Prior FY 2026 Guidance Current FY 2026 Guidance 1 Total revenue $6.3B - $6.5B $6.6B - $6.8B GAAP gross margin % High-80% range High-80% range GAAP operating expenses 2 (combined R&D and SG&A) $4.7B - $4.9B $4.8B - $5.0B GAAP operating income 2 $750M - $850M $1.0B - $1.1B Non-GAAP operating income 2,3 $1.45B - $1.55B $1.7B - $1.8B 1 Assumes August 1, 2026 foreign exchange rates. 2 Does not assume any potential new, material business development activity or unusual/non-recurring items. 3 Non-GAAP operating income is " exhibit
Q2 FY2026 "BeOne’s total revenue guidance for full year 2026 of $6.6 billion to $6.8 billion includes expectations for strong revenue growth driven by BRUKINSA’s leadership position in the U.S. and continued global expansion in both Europe and other important rest of world markets." exhibit
Q2 FY2026 "Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and a full year of 2026 productivity improvements." exhibit
Q2 FY2026 "Income tax outlook : Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized; the timing and magnitude of a potential reversal is uncertain; prior to reversal, income tax expense should trend with earnings per historical relationship." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ONC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ONC

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ONC earnings date badge

HTML

<a href="https://veritasdata.dev/company/ONC/"><img src="https://veritasdata.dev/embed/ONC.svg" alt="ONC earnings date" width="240" height="56"></a>

Markdown

[![ONC earnings date](https://veritasdata.dev/embed/ONC.svg)](https://veritasdata.dev/company/ONC/)

Script

<script async src="https://veritasdata.dev/embed/ONC.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ONC"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.